Introduction to BEPO ® STAR: Overview of the novel Medincell’s proprietary Long-Acting Injectable technology designed to enhance controlled delivery across a broader range of drugs and therapeutic ...
Hosted on MSN
Verrica Pharmaceuticals to Present Phase 2 Data on VP-315 at Major Immunotherapy Conference
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will present new data on its investigational oncolytic peptide therapy, VP-315, for the treatment of basal cell ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback